Lead sponsor
Huazhong University of Science and Technology
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
3
Trials led
2
Ongoing
1,349
Total enrollment
6
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
2
Not applicable
1
Trials by status
Not yet recruiting
2
Completed
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight LossBMI ≥28not applicableNot yet recruiting600
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)BMI ≥27Ph 4Not yet recruiting400
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMBMI 23-35Ph 4Completed349